Blood Biomarkers for Alzheimer’s Dementia Diagnosis
Alzheimer’s disease (AD) represents a major public health concern and has been identified as a research priority. Clinical research evidence supports that the core cerebrospinal fluid (CSF) biomarkers for AD, including amyloid-β (Aβ42), total tau (T-tau), and phosphorylated tau (P-tau), reflect key...
Main Author: | Chang-Eun Park |
---|---|
Format: | Article |
Language: | English |
Published: |
The Korean Society for Clinical Laboratory Science
2022-12-01
|
Series: | Korean Journal of Clinical Laboratory Science |
Subjects: | |
Online Access: | http://www.kjcls.org/journal/view.html?doi=10.15324/kjcls.2022.54.4.249 |
Similar Items
-
The potential of pathological protein fragmentation in blood-based biomarker development for dementia – with emphasis on Alzheimer’s disease
by: Dilek eInekci, et al.
Published: (2015-05-01) -
Novel Blood Biomarkers for an Earlier Diagnosis of Alzheimer’s Disease: A Literature Review
by: Shiavax J. Rao, et al.
Published: (2020-06-01) -
Salivary biomarkers: The early diagnosis of Alzheimer's disease
by: Sophia Nazir
Published: (2024-04-01) -
A circular RNA blood panel that differentiates Alzheimer’s disease from other dementia types
by: Ziye Ren, et al.
Published: (2022-08-01) -
Early Diagnosis of Alzheimer’s Disease: Moving Toward a Blood-Based Biomarkers Era
by: Tao QQ, et al.
Published: (2023-03-01)